Evidence map›Paper›PMID 41546097›Full record

ArticleCell communication and signaling : CCS2026

Interruption of cross-communication pathways alters the immune cell signature of pancreatic cancer and decreases tumor growth.

Jill P Smith, Mahdis Mohit, Joi Kenner, Ajay Nathan, Jack Drda, Martha D Gay, Hong Cao, Wenqiang Chen, Alison Gomeiz, Elisa Baldelli and 7 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jill P SmithDepartments of Medicine, Georgetown University, Washington, DC, USA. jps261@georgetown.edu.
Mahdis MohitDepartment of Biochemistry and Molecular Biology, Georgetown University, Washington, DC, USA.
Joi KennerUniversity of Maryland, College Park, MD, USA.
Ajay NathanDepartments of Medicine, Georgetown University, Washington, DC, USA.
Jack DrdaUniversity of Pittsburgh, Pittsburgh, PA, USA.
Martha D GayDepartments of Medicine, Georgetown University, Washington, DC, USA.
Hong CaoDepartments of Medicine, Georgetown University, Washington, DC, USA.
Wenqiang ChenDepartments of Medicine, Georgetown University, Washington, DC, USA.
Alison GomeizCenter for Applied Proteomics and Molecular Medicine/School of Systems Biology, Manassas, VA, USA.
Elisa BaldelliCenter for Applied Proteomics and Molecular Medicine/School of Systems Biology, Manassas, VA, USA.
Wenyu DouDepartment of Biostatistics, Georgetown University, Washington, DC, USA.
Hong-Bin FangDepartment of Biostatistics, Georgetown University, Washington, DC, USA.
Narayan ShivapurkarDepartments of Medicine, Georgetown University, Washington, DC, USA.
James DavisCenter for Applied Proteomics and Molecular Medicine/School of Systems Biology, Manassas, VA, USA.
Qi WeiDepartment of Bioengineering, George Mason University, Manassas, VA, USA.
Abdellah AkhrifDepartment of Bioengineering, George Mason University, Manassas, VA, USA.
Mariaelena PierobonCenter for Applied Proteomics and Molecular Medicine/School of Systems Biology, Manassas, VA, USA.

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI MARCUS S NOEL · 1990 to 2026
$71.5M
The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesisR01CA277680 · NCI · GEORGETOWN UNIVERSITY · PI Jill P Smith · 2023 to 2026
$2.4M
American Cancer Society DICR INTR-23American Physiological Society No numberNCI NIH HHS P30 CA051008NCI NIH HHS P30-CA051008NCI NIH HHS R01 CA277680NIH HHS R01CA277680
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited therapeutic options in part due to a dense stroma and the ability of the tumor cells to defy therapy by creating an immunosuppressive milieu. A histologic feature of PDAC is the abundance of immunosuppressive M2-polarized tumor-associated macrophages (TAMs) that favor cancer growth and metastases. Cancer cells communicate with immune cells of the tumor microenvironment (TME) by several mechanisms including exosomes to induce plasticity of the immune cells favoring pro-cancer instead of anti-cancer phenotypes. We examined a novel strategy to interrupt the cross-communication between cancer and immune cells by reprogramming the TME with a cholecystokinin-B receptor (CCK-BR) antagonist, proglumide.

methodsCross-communication was examined using 3-dimensional human PDAC spheroids that were either co-cultured with macrophages or treated with supernatant spent media from macrophages. RNA was extracted from the spheroids and subjected to RNA sequencing and Reverse Phase Protein Array (RPPA). RNA sequencing revealed that the most upregulated gene in the cancer cells after co-culture was ELANE, which codes for neutrophil elastase. Next, ELANE expression was down regulated by shRNA transfection in PDAC cells and the effect of the decreased expression was examined on the polarization of immune cells in vitro and in vivo in mice. Exosomes were also collected from PDAC spheroids for evaluation by RPPA.

resultsCo-culture of spheroids with macrophages increased cancer cell number and induced polarization of M0 macrophages to the M2-phenotype. Co-culture increased oncogenic pathways and genes by RPPA and RNA sequencing, respectively, and these changes were reversed with proglumide. ELANE knockdown in PDAC cells prevented the M2-polarization of macrophages in vitro and decreased tumor growth in vivo. Immunohistochemistry of ELANE knockdown tumors showed a shift in plasticity from M2-polarized TAMs to M1-polarized cells compared to wild-type tumors. Neutrophil elastase in cancer exosomes increased after co-culture and was abolished by treatment with proglumide.

conclusionELANE expression in PDAC cells regulates polarization of macrophages through the release of neutrophil-elastase rich exosomes. Proglumide therapy with CCK-B receptor antagonism is a novel method to interrupt cross-communication pathways between PDAC and immune cells in the TME and decrease cancer growth.

Indexed as

Carcinoma, Pancreatic DuctalCell CommunicationPancreatic NeoplasmsAnimalsCell Line, TumorCell ProliferationCoculture TechniquesGene Expression Regulation, NeoplasticHumansMacrophagesMiceSpheroids, CellularTumor MicroenvironmentCell signalingCytokinesNeutrophil elastasePancreatic cancerTumor-associated macrophagesTumor microenvironment

Identifiers

PMID41546097
PMCPMC12859874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.